Locksley Resources (ASX: LKY) hits 99.5% purity antimony trioxide milestone, opening U.S. defense supply chain pathway
How Accenture is using Google Cloud and Wiz to close security blind spots in modern multi-cloud infrastructure
Read More 6 minute read Pharma Industry News CVKD expands clinical pipeline with acquisition of VLX-1005, a Phase 2 12-LOX inhibitor for HIT patients Discover how Cadrenal Therapeutics’ acquisition of VLX-1005 could reshape treatment options for heparin-induced thrombocytopenia and strengthen its anticoagulation pipeline. bySoujanya RaviDecember 13, 2025